Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion evidence source_evidence_literature NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion SIO_000772 24646054 NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion wasDerivedFrom befree-20150227 NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion wasGeneratedBy ECO_0000203 NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.